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Abstract
Background: In tuberculosis (TB)-endemic areas, contrast-enhanced computed tomography (CT) and positron emission
tomography (PET) findings of lung cancer patients with non-enlarged lymph nodes are frequently discrepant.
Endobronchial ultrasound-guided transbronchial aspiration (EBUS-TBNA) enables real-time nodal sampling, and thereby
improves nodal diagnosis accuracy. This study aimed to compare the accuracy of nodal diagnosis by using EBUS-TBNA, and
PET.
Methods: We studied 43 lung cancer patients with CT-defined non-enlarged mediastinal and hilar lymph nodes and
examined 78 lymph nodes using EBUS-TBNA.
Results: The sensitivity, specificity, positive predictive value, and negative predictive value of EBUS-TBNA were 80.6%, 100%,
100%, and 85.7%, respectively. PET had low specificity (18.9%) and a low positive predictive value (44.4%). The diagnostic
accuracy of EBUS-TBNA was higher than that of PET (91% vs. 47.4%; p,0.001). Compared to CT-based nodal assessment,
PET yielded a positive diagnostic impact in 36.9% nodes, a negative diagnostic impact in 46.2% nodes, and no diagnostic
impact in 16.9% nodes. Patients with lymph nodes showing negative PET diagnostic impact had a high incidence of
previous pulmonary TB. Multivariate analysis indicated that detection of hilar nodes on PET was an independent predictor of
negative diagnostic impact of PET.
Conclusion: In a TB-endemic area with a condition of CT-defined non-enlarged lymph node, the negative diagnostic impact
of PET limits its clinical usefulness for nodal staging; therefore, EBUS-TBNA, which facilitates direct diagnosis, is preferred.
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Introduction
Lung cancer remains a fatal disease worldwide, and surgical
treatment may offer long-term survival. However, the indication
and outcome of surgical resection depend on accurate preoper-
ative staging of the cancer and the extent of intraoperative lymph
node dissection [1,2,3]. Therefore, accurate lymph node staging in
patients with non-small cell lung cancer (NSCLC) is crucial for
planning the optimal treatment. Conventional contrast-enhanced
computed tomography (CT) has been used to identify enlarged
lymph nodes; lymph nodes .1 cm are defined as nodal metastatic
lesions. However, because it is moderately sensitive and
pecific, contrast-enhanced CT carries a substantial risk of under-
staging small nodal metastasis and overstaging inflammatory
lymphadenitis [4].
Positron emission tomography (PET) using fluorine-18 fluor-
odeoxyglucose (
18F-FDG) provides functional information about
tumor metabolism and has been used as a non-invasive alternative
to contrast-enhanced CT for nodal staging in NSCLC [5,6,7]. In
some countries, FDG-PET is increasingly being used for lymph
node staging in NSCLC when lymph node enlargement is not
detected by CT. Therefore, the accuracy afforded by FDG-PET
may substantially alter the treatment strategy in institutions in
which mediastinoscopy is unavailable for lymph node sampling.
However, abnormal FDG uptake is believed to frequently occur in
granulomatous and inflammatory diseases [8,9]. In tuberculosis
(TB)-endemic areas such as Eastern Asia, FDG-PET has been
reported to have low specificity and a positive predictive value in
nodal staging in NSCLC [10,11,12]. Therefore, in such areas, the
PET scan does not appear to replace mediastinoscopy for nodal
staging of NSCLC [11], especially in the case of potentially
operable patients without enlarged mediastinal lymph nodes.
The recently developed endobronchial ultrasound-guided
transbronchial aspiration (EBUS-TBNA) procedure enables direct
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is a less invasive alternative to mediastinoscopy for nodal staging
[13,14]. Unlike CT and FDG-PET, in which lymph node stage is
determined on the basis of the results of image analysis, EBUS-
TBNA enables direct nodal sampling; therefore, nodal staging can
be performed on the basis of the results of cytological or
pathological examination. However, EBUS-TBNA has been
reported to have variable sensitivity and negative predictive value
[13,15], especially in cases wherein the size of the lymph nodes has
been reduced by induction chemotherapy [16]. However, EBUS-
TBNA has been reported to show high sensitivity and specificity
for detecting small nodal metastasis in NSCLC patients without
significant mediastinal lymph node enlargement on CT [17,18].
Therefore, whether EBUS-TBNA shows high diagnostic accuracy
for nodal staging in lung cancer patients without enlarged
mediastinal lymph nodes on CT in a TB-endemic country—a
condition for which FDG-PET has shown much negative
diagnostic impact, i.e. false-positive results—remains to be
clarified.
In this study, we primarily aimed to compare the diagnostic
accuracy of EBUS-TBNA and FDG-PET in lung cancer patients
with CT-defined non-enlarged mediastinal and hilar lymph nodes.
Further, we also aimed to look at the diagnostic impact of FDG-
PET in this condition, and investigated the characteristics of
lymph nodes which accounted for either negative or positive
diagnostic impact on FDG-PET.
Materials and Methods
Study subjects
Between January 2007 and January 2009, nodal sampling by
using EBUS-TBNA was performed in 43 lung cancer patients with
non-enlarged mediastinal and hilar lymph nodes defined by
contrast-enhanced CT examination. Written informed consent
was obtained from all study subjects and the institutional review
board of Chang Gung Memorial Hospital approved the study
(No. 98-3639A3).
Imaging techniques
Contrast-enhanced CT was initially performed in the 45
patients included in the study to examine lung parenchymal and
mediastinal lesions. CT images were obtained from the thoracic
inlet to the adrenal gland, and the images were assessed by an
experienced radiologist who was blinded to the FDG-PET and
pathology reports. Non-enlarged mediastinal and hilar lymph
nodes were defined as lymph nodes with short-axis diameters
#10 mm on contrast-enhanced CT of the chest. The attending
physician referred patients for FDG-PET by considering each
patient’s will and payment of personal medical insurance. Each
patient was instructed to fast for 6 h before undergoing PET and
was intravenously injected with 370 MBq (10 mCi) of
18F-FDG
60 min before the examination.
18F-FDG PET images were
obtained using an ECAT EXACT HR+ camera (Siemens/CTI
Inc., Knoxville, TN) by using full width at half-maximum of
4.5 mm and a transaxial field of view of 15 cm. Transaxial,
sagittal, and coronal tomographs were assessed primarily to
determine obvious abnormal foci of increased FDG uptake. All the
images were double-read by two nuclear physicians with more
than 6 years experience in PET interpretation, and the
discrepancies were resolved by discussion. A visual analysis score
(VAS) using a 4-point scale was primarily used to determine
18F-
FDG uptake in the lymph nodes, and the standardized uptake
value was used as an accessory reference. The 4-point scale
considered both the intensity of
18F-FDG uptake in the lymph
nodes and the contrast between the background mediastinum and
lymph nodes showing
18F-FDG accumulation. Accordingly, the 4-
point scale was developed as follows: 1, intensity of focal uptake of
18F-FDG lower than that of mediastinal uptake (benign lesion); 2,
intensity of focal uptake of
18F-FDG equal to that of mediastinal
uptake (equivocal for malignancy); 3, intensity of focal uptake of
18F-FDG greater than that of mediastinal uptake (possibility of
malignancy); and 4, intensity of focal uptake of
18F-FDG
significantly greater than that of mediastinal uptake (high
probability of malignancy). A VAS of 3 or 4 was considered
positive, whereas a score of 1 or 2 was considered negative. PET
scan results of 32 patients were available at the time of data
analysis. Two patients were excluded from EBUS-TBNA test due
to metastatic disease noted by PET. Compared to CT-based nodal
assessment, we interpreted a true-positive PET result as having
positive diagnostic impact and a false-positive PET result as having
negative diagnostic impact, categorizing either a true-negative or
false-negative PET result as having no diagnostic impact (i.e. PET
showed a same nodal assessment as CT).
EBUS-TBNA
All of the patients underwent TBNA via a flexible ultrasound-
guided bronchoscope with a linear scanning probe on the tip (BF-
UC206F-OL8, Olympus) EBUS-TBNA were performed by two
well-trained operators both have had experience in more than 30
cases, and the bronchoscopic operators were blinded to the PET
scan result. The curved probe scanned in a direction parallel to
that of the bronchoscope insertion, and the obtained images were
linked to an ultrasound scanner (EU-2000C, Olympus) with
Doppler-flow imaging. Conscious sedation was induced in all
patients by using midazolam before the bronchoscope was
inserted. Ultrasound examination of the hilar lymph node (stations
10, 11) was followed by subcarinal (station 7) and mediastinal
lymph nodes (stations 4, 2, 1). When a lymph node was visualized,
the picture was recorded and selected cursors were used to
measure its size 2-dimensionally. Lymph nodes with short-axis
diameters .5 mm were selected for subsequent real-time EBUS-
guided TBNA with a 22-gauge needle (NA-201SX-4022, Olym-
pus). The needle was passed at least 2 times for each targeted
lymph node. An internal sheath was placed inside the needle to
avoid contamination of the bronchial epithelium during each
puncture, and the sheath was removed after passage of the needle
into the targeted lymph node. Cytological examination of the
specimens was performed by a pathologist blinded to the patients’
clinical histories and imaging results. Pathological examination of
the specimen was also performed when a tissue core was obtained
by TBNA.
Statistical analysis
The result of each diagnostic modality was compared with that
of the surgical specimen obtained by extensive lymph node
dissection in 30 (69.8%) patients. Mediastinoscopy was performed
to approach N2 level lymph nodes in 5 patients; in them, biopsy
specimens were used for standard comparison. Eight patients
refused any sort of approach for diagnosis of mediastinal lymph
node involvement or treatment. Neither did they receive surgery
nor chemotherapy or radiotherapy. A series of CT scan image
follow-up was done in those patients; in that, 20% increase in
short-axis of a lymph node within 3 months was used to defined
pre-existing metastasis The sensitivity, specificity, positive predic-
tive value, and negative predictive value of each diagnostic
modality were calculated according to the standard definition. The
chi-squared test was used to compare differences between groups.
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Results
Patients and lymph node characteristics
We included a total of 43 lung cancer patients (25 men and 18
women; median age: 66 years) with non-enlarged mediastinal and
hilar lymph nodes. Baseline characteristics of the patients are
shown in Table 1. Results are expressed as mean (SD). The
patients were diagnosed with the following conditions: adenocar-
cinoma in 29 (69%), squamous cell carcinoma in 4 (9.5%), large
cell carcinoma in 1 (2.4%), undetermined NSCLC in 6 (14.3%),
and small cell carcinoma in 2 (4.8%). We performed EBUS-TBNA
in these patients and examined a total of 78 lymph nodes that had
a mean long axis and mean short axis of 9.5 mm (3.8 mm) and
6.8 mm (1.4 mm), respectively. Lymph nodes located in the
following regions were targeted: highest mediastinal, 1 (1.3%);
right upper paratracheal, 3 (3.8%); left upper paratracheal, 1
(1.3%); right lower paratracheal, 20 (47.6%); left lower paratra-
cheal, 9 (21.4%); subcarinal, 23 (54.8%); right hilar, 12 (28.6%);
left hilar, 5 (11.9%); right interlobar, 2 (2.6%); and left interlobar,
2 (2.6%).
Diagnostic value of PET and EBUS-TBNA
The results of each diagnostic modality on a per lymph node
basis are shown in Table 2. The sensitivity, specificity, positive
predictive value, and negative predictive value were 80.6%, 100%,
100%, and 85.7%, for EBUS-TBNA and 85.7%, 18.9%, 44.4%,
and 63.6% for PET, respectively. Thus, in our study, the
diagnostic accuracy of EBUS-TBNA was higher than that of
PET (91% vs. 47.4%; p,0.001). Further, when primary tumor site
was considered during interpretation of the PET results, the
contralateral lymph nodes with
18F-FDG uptake scores of 3 or 4
were deemed PET negative. Thus, the accuracy of the modified
method in which PET results were interpreted on the basis of the
primary tumor site was still lower than that of the EBUS-TBNA
results (52.3% vs. 91%, p,0.001). When lymph nodes were
positive for malignancy by EBUS-TBNA irrespective of PET
findings (PET-positive, n=19; PET-negative, n=3), the predictive
value of EBUS-TBNA for lymph nodes diagnosis was 100%
(Fig. 1). When lymph nodes were negative for malignancy by both
EBUS-TBNA and PET (n=8), the predictive value of both tests
were 87.5%. In the case of EBUS-TBNA-negative and PET-
positive lymph nodes (n=35), predictive value was 85.7% in favor
of the negative EBUS-TBNA result.
Diagnostic impact of PET
Compared to CT-based nodal assessment, 24 nodes detected by
PET were true-positive, yielding a 36.9% positive impact
incidence (Table 3). Thirty nodes detected by PET were false-
positive, which accounted for a 46.2% negative impact incidence.
Seven and 4 lymph nodes were PET-true-negative and PET-false-
negative, respectively, and were together responsible for a 16.9%
incidence of no impact. Patients with lymph nodes yielding
negative PET scan diagnostic impact were thoroughly investigated
to rule out the presence of pulmonary diseases other than lung
cancer. Of the 17 patients examined, 7 (41.2%) had previous
pulmonary TB, 3 (17.6%) had pneumoconiosis, 1 (5.9%) had
pulmonary fibrosis, and 6 (35.3%) had no history of pulmonary
disease. Rrepresentative cases of PET-negative diagnostic impact
due to previous pulmonary TB with granulomatous nodal
inflammation and anthracosilicosis diagnosed by EBUS-TBNAare
shown in Fig. 2 and 3.
Factors predicting the diagnostic impact of PET
The characteristics of lymph nodes yielding PET-positive
impact were compared to those yielding PET-negative impact
(Table 4). Four variables, namely lymph node size, lymph node
location, PET scale, and presence of calcification were reviewed as
factors predicting the diagnostic impact of PET. Among the PET-
positive impact lymph nodes, 21 (87.5%) were located in the
mediastinum and 3 (12.5%) were located in the hilum. In contrast,
in the PET-negative impact group, 14 (46.7%) lymph nodes were
located in the mediastinum and 16 (53.3%) were located in the
Table 1. Baseline characteristics of lung cancer patients with
CT-defined radiologically normal mediastinum.
Variables
Total patients, no. (men/women) 43 (25/18)
Median age, years 66
Lymph node size by CT, mm, mean (SD)
Short axis 6.8 (1.4)
Final diagnosis, no. (%)
Adenocarcinoma 29 (69)
Squamous cell carcinoma 4 (9.5)
Large cell carcinoma 1 (2.4)
Undetermined NSCLC 6 (14.3)
Small cell carcinoma 2 (4.8)
Location of lymph nodes targeted by EBUS-TBNA, no. (%)
Highest mediastinal (#1) 1 (1.3)
Right upper paratracheal (#2R) 3 (3.8)
Left upper paratracheal (#2L) 1 (1.3)
Right lower paratracheal (#4R) 20 (47.6)
Left lower paratracheal (#4L) 9 (21.4)
Subcarinal (#7) 23 (54.8)
Right hilar (#10R) 12 (28.6)
Left hilar (#10L) 5 (11.9)
Right interlobar (#11R) 2 (2.6)
Left interlobar (#11L) 2 (2.6)
Total 78 (100)
CT: computed tomography; NSCLC: non-small cell lung cancer; EBUS-TBNA:
endobronchial ultrasound-guided transbronchial aspiration.
doi:10.1371/journal.pone.0016877.t001
Table 2. Diagnostic values of PET and EBUS-TBNA in lung
cancer patients with CT-defined radiologically normal
mediastinum.
Tests
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Accuracy
(%)
PET 85.7 18.9 44.4 63.6 47.7
PET
* 69.2 41.0 43.9 66.7 52.3
EBUS-TBNA 80.6 100 100 85.7 91.0
*PET judgment directed by primary tumor location: Contralateral lymph nodes
with 3 or 4-point scale FDG uptake were judged as having a negative PET result.
CT: computed tomography; PET: positron emission tomography; EBUS-TBNA:
endobronchial ultrasound-guided transbronchial aspiration.
doi:10.1371/journal.pone.0016877.t002
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were scored as 3 and 17 (70.8%) were scored as 4. In contrast, in
the PET-negative impact group, 20 (66.7%) lymph nodes were
scored as 3 and 10 (33.3%) were scored as 4. Therefore, PET-
positive hilar lymph nodes (53.3% vs. 12.5%, p,0.01) and lymph
nodes scored as 3 (66.7% vs. 29.2%, p,0.05) were considered
significant predictors of PET-negative nodal diagnostic impact.
However, lymph node size and the presence of lymph node
calcification did not predict PET result accuracy. The contribution
of each predictor yielding PET-negative diagnostic impact was
analyzed by multivariate logistic regression. The PET-positive
finding of hilar lymph nodes (odds ratio [OR]: 5.75, 95% CI:
1.32–25.11, p,0.05), not lymph nodes scored as 3 points (OR:
3.21, 95% CI: 0.86–12.05, p=0.08), was identified as the single
independent predictor for PET-negative diagnostic impact
(Table 5).
Diagnostic value of PET in determining distant metastasis
In 32 patients receiving PET exam, 3 were suspicious of distant
metastasis. Two of them were excluded from EBUS-TBNA study
due to lumbar spine metastasis proved by pathology, and the other
one was proved to have cholecystitis. Hence; in the present study,
the sensitivity, specificity and accuracy for PET to identified
distant metastasis were 100%, 96.7% and 96.9%, respectively.
Discussion
In our study, EBUS-TBNA had higher accuracy than PET for
nodal diagnosis of lung cancer with CT-defined non-enlarged
lymph nodes. In addition, presence of an
18F-FDG-positive hilar
lymph node was an independent predictor for PET-negative
diagnostic impact. Moreover, patients with lymph nodes yielding a
PET-negative diagnostic impact showed a high incidence of
inflammatory lung disease, especially those with previous pulmo-
nary TB.
The strength and limitation of EBUS-TBNA in diagnosing
lymph nodes metastasis has been reported in either TB or non-TB
endemic country. The specificity was 100% in general; with a wide
range of sensitivity from 69% to 94% [14,15,17,19,20,21].
However, the diagnostic performance of EBUS-TBNA in lung
cancer with non-enlarged lymph nodes has only been primarily
studied in non-TB endemic country. Herth et al. reported a 89%
Figure 1. Predictive value of EBUS-TBNA stratified by PET scan results. TP, true-positive; TN, true-negative; FP, false-positive; FN,
false-negative.
doi:10.1371/journal.pone.0016877.g001
Table 3. Diagnostic impact of PET in CT-defined radiologically normal mediastinum.
Impact Positive None Negative
Diagnosis TP TN FN FP
*
No. (%) 24 (36.9%) 7 (10.8%) 4 (6.1%) 30 (46.2%)
*Seven patients (41.2%) previously had pulmonary tuberculosis, 3 (17.6%) previously had pneumoconiosis, 1 (5.9%) previously had pulmonary fibrosis, and 6 (35.5%)
had no previous lung disease.
doi:10.1371/journal.pone.0016877.t003
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status of NSCLC patients in whom the mediastinum appears
normal on radiography [17,18], a condition defined by lymph
nodes with short-axis diameters ,1 cm on contrast-enhanced CT.
The current study conducted in a TB-endemic country also
primarily aimed at lung cancer patients with non-enlarged lymph
nodes. The result has shown an 80.6% sensitivity of EBUS-TBNA,
which was comparable to the historical results in non-TB endemic
area.. We reported a 53.8% negative predictive value of CT-
defined negative mediastinal and hilar lymph nodes, and this value
is not satisfactory but is similar to the result reported in another
study [22]. Furthermore, our results show that PET has low
diagnostic accuracy (47.7%) for determining nodal status, which
can be mainly attributed to a high rate of false-positive results
(46.2%), a negative diagnostic impact of PET frequently happened
in TB-endemic areas.
The development of FDG-PET is considered major progress in
the field of oncology that has led to advancement of assessment of
the functional and molecular bases of tumors. However, F
18-
uptake in activated white blood cells interferes with that in tumor
cells; therefore, false-positive findings in inflammatory and
granulomatous lung diseases can be attributed to interference in
F
18-uptake [23]. Several reports from Asian countries indicate that
PET has a 15–25% chance of overstaging potentially operable
NSCLC [11,12]. Management of these patients would be
substantially altered accordingly if an invasive technique for nodal
staging were unavailable [24,25]. A history of pulmonary TB,
despite inactive infection at the time of assessment, was reported to
be the leading cause for the false-positive PET results
[10,11,12,26]. In our study, among the patients with lymph nodes
yielding negative diagnostic impact of PET, 64.7% had various
inflammatory lung diseases. Previous pulmonary TB was the
leading cause of inflammatory lung disease, followed by pneumo-
coniosis. These parenchymal lung diseases develop from focal
inflammation and spread via lymphatic drainage [27]. Hilar
lymph nodes are the sentinel gates that prevent infectious or pro-
inflammatory substances from reaching the mediastinum. This
may be attributed to the significantly high rate of false-positive
PET results for hilar lymph nodes. EBUS-TBNA could balance
the weakness of PET in such condition. In our study, a negative
Figure 2. A representative case of a PET scan with negative impact. (A) The contrast-enhanced CT scan shows small lymph nodes measuring
0.860.6 cm in the subcarinal area. (B) The PET scan shows increased FDG uptake at the corresponding site (gall bladder uptake due to cholecystitis).
(C) The subcarinal lymph node was later targeted by EBUS-TBNA(D) A tissue core, which revealed granulomatous inflammation consisting of
epithelioid histiocytes (upper right; H&E stain, 2006) was obtained.
doi:10.1371/journal.pone.0016877.g002
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0.860.8 cm in para-tracheal area (4R). (B) The PET scan shows strong FDG uptake (arrow) at the corresponding site. (C) Lymph node is targeted by
EBUS-TBNA, with the superior vena cava (SVC) lies beneath. (D) The pathology reveals collagenized nodules and anthracotic pigment-laden
macrophages (H&E stain, 100X). Silica particles were identified under polarized light (not shown).
doi:10.1371/journal.pone.0016877.g003
Table 4. Predictors for nodal diagnostic impact of PET scan in
CT-defined radiologically normal mediastinum.
Variables Positive impact Negative impact p value
Size
short axis, mm, mean (SD) 6.9 (1.5) 6.5 (1.1) 0.35
Location
hilar (#10, #11) 3 16
mediastinal (#1, #2, #4, #7) 21 14 0.003
PET scale
3-points 7 20
4-points 17 20 0.01
Calcification
with 3 7
without 21 23 0.48
doi:10.1371/journal.pone.0016877.t004
Table 5. Multivariate logistic regression analysis of predictors
for negative nodal diagnostic impact of PET scan.
Variables OR (95% CI) p value
Size
short axis 0.97 (0.59–1.60) 0.90
Location
hilar vs. mediastinal 5.75 (1.32–25.11) 0.01
PET scale
3 points vs. 4-points 3.21 (0.86–12.05) 0.08
Calcification
with vs. without 1.09 (0.20–6.00) 0.93
doi:10.1371/journal.pone.0016877.t005
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negative predictive value. On the other hand, a same finding from
mediastinal lymph nodes showed an 80% negative predictive
value. A large proportion of false-positive PET hilar lymph nodes
in patients with no previous history of TB may be attributed to
primary TB infection since a high percentage of adults in Taiwan
are purified protein derivative (PPD)-positive [28,29].
In our study, due to a high rate of false-positive results, the
accuracy of PET for nodal diagnosis in cases of lung cancer
patients with non-enlarged mediastinal and hilar lymph nodes did
not increase. However, our results do not dispute the value of PET
in detecting malignant lymph nodes on the basis of
18F-FDG
uptake by the lymph nodes. The high sensitivity (85.7%) suggests
that PET potentially can be used as a screening method to detect
lymph nodes that are ,1 cm. However, the high false-positive rate
observed in hilar nodes warrants further investigation. A dual-
time-point evaluation of FDG uptake, which combines standard
uptake value with a retention index, has been proposed to improve
lymph node diagnosis in NSCLC [30,31]. However, other studies
have reported controversial results of the superiority of dual-time-
point evaluation technique over conventional VAS [32,33]. On
the other hand, our results show that the sensitivity and specificity
of PET for distant metastasis is high; therefore, PET is an
important staging tool to exclude distant metastasis.
In current study, we included lung cancer patients with non-
enlarged lymph nodes to investigate the frequent clinical
discrepancy between CT and PET results, but this was at the
expense of a larger study population. However, the power of
primary aim was not hampered by sample size because of the large
effect size, i.e. the diagnostic accuracy difference of EBUS-TBNA
and PET. In addition, PET imaging was performed on an older
PET-only scanner, without CT correlation to intra-thoracic
structures. This might be difficult for PET readers to determine
whether the activity seen on PET correlates to lymph node or
other structures. Whether use of integrated PET/CT might
improve the accuracy deserves further investigation. However,
given the dated technology of the scanner, it may not be enough to
overcome the limited nature of PET arm of this study.
In conclusion, a high proportion of lung cancer patients with
non-enlarged mediastinal and hilar lymph nodes on contrast-
enhanced CT were found to have mediastinal or hilar lymph node
metastasis. In a TB-endemic area, a high rate of negative
diagnostic impact limits the clinical usefulness of PET for nodal
staging; therefore, we recommend direct tissue sampling using
EBUS-TBNA for nodal staging.
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